Lenacapavir, a twice-yearly injectable HIV prevention drug, significantly reduces new infections among vulnerable populations, but high costs and distribution gaps threaten broad access, according to global health experts. For young women and marginalized groups facing high risks of transmission, the long-acting injection offers an alternative to daily oral pills, though public health officials warn that the drug alone cannot eliminate the epidemic.

How Lenacapavir Prevents HIV Infection

Unlike traditional Pre-Exposure Prophylaxis (PrEP) pills that block enzymes during viral replication, lenacapavir targets the capsid, a cone-shaped shell surrounding the virus’s genetic material. According to Wesley Sundquist, a University of Utah biochemist and leading expert on the HIV capsid, the molecule remains potent even at low concentrations and forms a small depot in the body that slowly dissolves.

Lenacapavir is the most potent molecule known against HIV, Sundquist told DW. The drug requires just one injection every six months, contrasting sharply with daily oral regimens that face severe adherence drop-offs within months of starting.

Adherence Challenges with Daily PrEP Pills

Daily oral PrEP demands that healthy individuals maintain strict routines, creating a high barrier to continuous protection. According to Salim Abdool Karim, director and co-founder of the Centre for the AIDS Programme of Research in South Africa, repeat studies show that by month three, about half of patients give up daily PrEP, leaving only a handful still taking it by the end of the year.

Users often forget doses, experience side effects, resent daily pill burdens, or fear that relatives or partners will discover the medication and cause stigma. Lenacapavir eliminates that daily pill burden for individuals who receive the injection every six months without fail, according to Abdool Karim.

Did You Know?

Mathematical modeling by University of Washington epidemiologist Monisha Sharma shows that providing lenacapavir to approximately 2–4% of the adult population in South Africa, Zimbabwe, and western Kenya, with targeted uptake among people at greatest risk, averted approximately 12–18% of new infections over ten years.

Access Barriers and Exclusions in Global Rollouts

Despite clinical trial participation, several Latin American countries including Brazil, Mexico, Peru, and Argentina have been excluded from recent rollouts of lenacapavir, according to Melissa Scharwey of Doctors Without Borders (MSF). Even inside eligible nations, vulnerable groups frequently miss out on supplies.

Scharwey noted that supply remains inadequate, urging developer Gilead to increase production and sell directly to MSF at an affordable price of roughly $40 per shot. In South Africa, a rollout for high-risk populations began in June 2026, supported by an agreement where Gilead supplies lenacapavir at no profit to up to 2 million people over three years, following a prior deal allowing generic production in 120 resource-limited countries.

Reaching High-Risk Populations Remains the Core Obstacle

While lenacapavir solves adherence for treated individuals, public health experts emphasize that distribution alone does not guarantee epidemic control. According to Abdool Karim, the hardest challenge involves reaching individuals in greatest danger who often fail to recognize their own vulnerability.

If health programs cannot reach those at highest risk, the epidemic will not see the expected decline, Abdool Karim explained. Monisha Sharma added that lenacapavir’s impact depends entirely on affordable pricing, efficient distribution channels, and targeted uptake among populations with the highest exposure.

Frequently Asked Questions

What is lenacapavir?

Lenacapavir is a long-acting injectable antiviral medication used for HIV prevention that targets the viral capsid and requires administration once every six months.

How does lenacapavir differ from daily PrEP pills?

While daily oral PrEP requires patients to take a pill every day—a routine that many abandon within months—lenacapavir is administered as a biannual injection, ensuring near-complete adherence for those who receive it on schedule.

Which groups are prioritized for lenacapavir rollouts?

Experts point to adolescent girls and young women in parts of Africa, younger gay men in the West, and vulnerable gay communities in Eastern Europe and Central Asia as key groups needing urgent access.

Is lenacapavir widely available globally?

Access remains uneven, with high prices and supply constraints affecting several regions. Certain Latin American nations have been excluded from recent distribution deals despite participating in clinical trials.